Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline
Company’s Phase 1/2 Clinical Trial of EN-374 in X-linked Chronic Granulomatous Disease is Now Open for Patient Enrollment BOSTON–(BUSINESS WIRE)–Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of…